drugset / Trial / NCT03130452

Helicobacter Pylori Eradication Study

NCT03130452

Phase 4 Completed 423 enrolled Inje University
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of H. pylori eradication.

Timeline

Start
2016-12-17
Primary completion
2019-01-28
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g Oral
Subject Clarithromycin Small molecule 500 mg Oral
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Metronidazole Small molecule 500 mg Oral